NCT00310531View on ClinicalTrials.gov

3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women

PHASE3CompletedINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

February 29, 2004

Study Completion Date

June 30, 2007

Conditions
Osteopenia
Interventions
DRUG

Menostar (Estradiol, BAY86-5435)

Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)

DRUG

Raloxifene

Raloxifene tbl. (60 mg/day)

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY